 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31st Annual Healthcare Conference and Stifels 3rd Annual CNS Day. Conferences Details: Event: Oppenheimer 3 